# Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

> **NCT03414450** · PHASE1 · WITHDRAWN · sponsor: **EDDC (Experimental Drug Development Centre), A*STAR Research Entities**

## Conditions studied

- Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
- Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
- Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)
- Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)

## Interventions

- **DRUG:** ETC-1907206
- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT03414450
- **Lead sponsor:** EDDC (Experimental Drug Development Centre), A*STAR Research Entities
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-25
- **Primary completion:** 2022-02
- **Final completion:** 2023-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawal requested by D3
- **Last updated:** 2018-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03414450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03414450, "Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03414450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*